This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Shinshu University, Other. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2021
Title: Kousaku Ohkawa: Innovator in Liquid Embolic Agents
Introduction
Kousaku Ohkawa is a notable inventor based in Nagano, Japan. He has made significant contributions to the field of medical technology, particularly in the development of liquid embolic agents. His innovative work addresses critical challenges in treating vascular diseases.
Latest Patents
Ohkawa holds a patent for a liquid embolic agent composition. This composition is designed to overcome the limitations of conventional embolic agents used in treating vascular diseases, such as cerebral aneurysms. The patented composition includes a hydrogel forming component with calcium ion entrapping ability and an anti-biodegradation component. The hydrogel forming component consists of acidic polysaccharides like alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt. The anti-biodegradation component includes substances such as hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate.
Career Highlights
Throughout his career, Kousaku Ohkawa has worked at Shinshu University, where he has contributed to research and development in medical technologies. His work has been instrumental in advancing the understanding and application of liquid embolic agents in clinical settings.
Collaborations
Ohkawa has collaborated with notable colleagues, including Ichiro Yuki and Takaomi Nomura. These collaborations have further enriched his research and innovation efforts in the medical field.
Conclusion
Kousaku Ohkawa's contributions to the development of liquid embolic agents highlight his role as an innovator in medical technology. His patented work addresses significant medical challenges and showcases the potential for advancements in treating vascular diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile